"Personalized medicine," "precision medicine," "pharmacogenomics" or whatever you want to call it, it's pretty clear the industry is moving in the direction of having drugs to treat patients based on their genetic makeup.
Biotechs often set up subsidiaries to house assets for tax reasons or to house programs unrelated to their core mission that might get spun off, but Moderna Therapeutics Inc. has a new twist, establishing "venture companies" focused on specific diseases.
Through the first four months of the year, BioWorld Snapshots tracked 24 IPOs by drug companies on U.S. and international exchanges compared to 36 in the same time period last year.
As with any new technology, it takes baby steps to get drugs through the regulatory process and onto the market. And nanomedince is no exception. The technology is certainly progressing, but at a methodical pace.
As with any new technology, it takes baby steps to get drugs through the regulatory process and onto the market. And nanomedince is no exception. The technology is certainly progressing, but at a methodical pace.
In spite of increased biotech valuations providing for access to capital through the equity markets, the market for capital from the sale of royalties and structured debt tied to product sales is as hot as it's ever been.
Neither snow in Boston nor a drought in California could stop venture capitalists from handing out cash in the first quarter to start-ups and established private companies alike.
With different mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) causing different severities of the disease and requiring different drugs to increase protein function, cystic fibrosis (CF) is the poster child of precision medicine.
Like the basketball Atlantic Coast Conference, the other ACC, the American College of Cardiology, ramps up this time of year with its annual scientific session.
